Valley Wealth Managers’s Biogen BIIB Stock Holding History

Valley Wealth Managers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-16	Closed	-$5K	–	208
2016 Q4	$5K	Buy	+16	New	+$4.74K	﹤0.01%	192

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Valley Wealth Managers's BIIB Position: Q1 2017 in Review

Valley Wealth Managers sold out of Biogen (BIIB) in Q1 2017, closing a stake of 16 shares — an estimated $5K sold.

Valley Wealth Managers first reported a position in BIIB in Q4 2016 and held it in 1 quarter. The position peaked at $5K in Q4 2016. 1,020 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

Valley Wealth Managers reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
Valley Wealth Managers sold 16 Biogen shares in Q1 2017, an estimated $5K.
Valley Wealth Managers first reported a position in Biogen in Q4 2016 and held it in 1 quarter.
Valley Wealth Managers's Biogen position peaked at $5K in Q4 2016.
1,020 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on Valley Wealth Managers's 13F filing for Q1 2017, filed 12 May 2017.